This information is intended for US healthcare professionals to access current scientific information about J&J Innovative Medicine products. It is prepared by Medical Information and is not intended for promotional purposes, nor to provide medical advice.
INVEGA Dosing - Chewing, Splitting, or Crushing Tablets
Last Updated: 07/31/2026
- INVEGA (paliperidone) Extended-Release Tablets use OROS®
(osmotic controlled release system) technology. OROS technology employs osmosis to provide precise, controlled drug delivery for up to 24 hours.1 - Due to the controlled drug delivery from the OROS technology, INVEGA tablets must be swallowed whole with the aid of liquids. Tablets should not be chewed, divided, or crushed.1
- INVEGA should only be used in patients who are able to swallow the tablet whole.1
- INVEGA is available in 1.5 mg, 3 mg, 6 mg, and 9 mg tablets. The 1.5 mg tablet is the recommended initial dose for patients with moderate to severe renal impairment.1
Please refer to the following sections of the enclosed Full Prescribing Information that are relevant to your inquiry: DOSAGE AND ADMINISTRATION, WARNINGS AND PRECAUTIONS, DESCRIPTION, and PATIENT COUNSELING INFORMATION.
A literature search of MEDLINE®, Embase®, BIOSIS Previews®, and Derwent Drug File (and/or other resources, including internal/external databases) pertaining to this topic was conducted on 24 September 2025. No relevant references were identified regarding chewing, splitting, or crushing paliperidone ER tablets.
References
| 1 | INVEGA (paliperidone) extended-release tablet [Prescribing Information]. Titusville, NJ: Janssen Pharmaceuticals, Inc; https://imedicalknowledge.veevavault.com/ui/approved_viewer?token=7994-d30da9a4-d8a4-4e37-b8e8-d52589dfe597 |
Would you like to clear and leave your conversation? Message history will be lost.